These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

618 related items for PubMed ID: 28822825

  • 1. Comparison of transforaminal lumbar interbody fusion outcomes in patients receiving rhBMP-2 versus autograft.
    Khan TR, Pearce KR, McAnany SJ, Peters CM, Gupta MC, Zebala LP.
    Spine J; 2018 Mar; 18(3):439-446. PubMed ID: 28822825
    [Abstract] [Full Text] [Related]

  • 2. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 2: BMP dosage-related complications and long-term outcomes in 509 patients.
    Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R.
    Spine (Phila Pa 1976); 2013 Jun 01; 38(13):1137-45. PubMed ID: 23354111
    [Abstract] [Full Text] [Related]

  • 3. RhBMP-2-induced radiculitis in patients undergoing transforaminal lumbar interbody fusion: relationship to dose.
    Villavicencio AT, Burneikiene S.
    Spine J; 2016 Oct 01; 16(10):1208-1213. PubMed ID: 27343729
    [Abstract] [Full Text] [Related]

  • 4. Clinical sequelae after rhBMP-2 use in a minimally invasive transforaminal lumbar interbody fusion.
    Singh K, Nandyala SV, Marquez-Lara A, Cha TD, Khan SN, Fineberg SJ, Pelton MA.
    Spine J; 2013 Sep 01; 13(9):1118-25. PubMed ID: 24029138
    [Abstract] [Full Text] [Related]

  • 5. Transforaminal lumbar interbody fusion with rhBMP-2 in spinal deformity, spondylolisthesis, and degenerative disease--part 1: Large series diagnosis related outcomes and complications with 2- to 9-year follow-up.
    Crandall DG, Revella J, Patterson J, Huish E, Chang M, McLemore R.
    Spine (Phila Pa 1976); 2013 Jun 01; 38(13):1128-36. PubMed ID: 23370679
    [Abstract] [Full Text] [Related]

  • 6. Nerve injury and recovery after lateral lumbar interbody fusion with and without bone morphogenetic protein-2 augmentation: a cohort-controlled study.
    Lykissas MG, Aichmair A, Sama AA, Hughes AP, Lebl DR, Cammisa FP, Girardi FP.
    Spine J; 2014 Feb 01; 14(2):217-24. PubMed ID: 24269858
    [Abstract] [Full Text] [Related]

  • 7. Complications associated with single-level transforaminal lumbar interbody fusion.
    Rihn JA, Patel R, Makda J, Hong J, Anderson DG, Vaccaro AR, Hilibrand AS, Albert TJ.
    Spine J; 2009 Aug 01; 9(8):623-9. PubMed ID: 19482519
    [Abstract] [Full Text] [Related]

  • 8. Comparison of TLIF with rhBMP-2 versus no TLIF and higher posterolateral rhBMP-2 dose at L5-S1 for long fusions to the sacrum with sacropelvic fixation in patients with primary adult deformity.
    Rahman RK, Buchowski JM, Stephens B, Dorward IG, Koester LA, Bridwell KH.
    Spine (Phila Pa 1976); 2013 Dec 15; 38(26):2264-71. PubMed ID: 24108280
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and safety of recombinant human bone morphogenetic protein-2 versus local bone graft in primary lumbar interbody fusions.
    Adams CL, Ogden K, Robertson IK, Broadhurst S, Edis D.
    Spine (Phila Pa 1976); 2014 Jan 15; 39(2):164-71. PubMed ID: 24153173
    [Abstract] [Full Text] [Related]

  • 10. Allogeneic morphogenetic protein vs. recombinant human bone morphogenetic protein-2 in lumbar interbody fusion procedures: a radiographic and economic analysis.
    Roh JS, Yeung CA, Field JS, McClellan RT.
    J Orthop Surg Res; 2013 Dec 28; 8():49. PubMed ID: 24373225
    [Abstract] [Full Text] [Related]

  • 11. Prospective, randomized, controlled trial of silicate-substituted calcium phosphate versus rhBMP-2 in a minimally invasive transforaminal lumbar interbody fusion.
    Nandyala SV, Marquez-Lara A, Fineberg SJ, Pelton M, Singh K.
    Spine (Phila Pa 1976); 2014 Feb 01; 39(3):185-91. PubMed ID: 24253788
    [Abstract] [Full Text] [Related]

  • 12. A comparison of radiographic and clinical outcomes of anterior lumbar interbody fusion performed with either a cellular bone allograft containing multipotent adult progenitor cells or recombinant human bone morphogenetic protein-2.
    Lee DD, Kim JY.
    J Orthop Surg Res; 2017 Aug 25; 12(1):126. PubMed ID: 28841904
    [Abstract] [Full Text] [Related]

  • 13. Radiographic Appearance of Transforaminal Lumbar Interbody Fusion Performed With and Without Recombinant Human Morphogenetic Protein-2.
    Stensby JD, Kaliney RW, Alford B, Shen FH, Patrie JT, Fox MG.
    AJR Am J Roentgenol; 2016 Mar 25; 206(3):588-94. PubMed ID: 26901016
    [Abstract] [Full Text] [Related]

  • 14. Symptomatic ectopic bone formation after off-label use of recombinant human bone morphogenetic protein-2 in transforaminal lumbar interbody fusion.
    Chen NF, Smith ZA, Stiner E, Armin S, Sheikh H, Khoo LT.
    J Neurosurg Spine; 2010 Jan 25; 12(1):40-6. PubMed ID: 20043763
    [Abstract] [Full Text] [Related]

  • 15. A Systematic Review of Lumbar Fusion Rates With and Without the Use of rhBMP-2.
    Galimberti F, Lubelski D, Healy AT, Wang T, Abdullah KG, Nowacki AS, Benzel EC, Mroz TE.
    Spine (Phila Pa 1976); 2015 Jul 15; 40(14):1132-9. PubMed ID: 25955186
    [Abstract] [Full Text] [Related]

  • 16. Does recombinant human bone morphogenetic protein-2 use in adult spinal deformity increase complications and are complications associated with location of rhBMP-2 use? A prospective, multicenter study of 279 consecutive patients.
    Bess S, Line BG, Lafage V, Schwab F, Shaffrey CI, Hart RA, Boachie-Adjei O, Akbarnia BA, Ames CP, Burton DC, Deverin V, Fu KM, Gupta M, Hostin R, Kebaish K, Klineberg E, Mundis G, O'Brien M, Shelokov A, Smith JS, International Spine Study Group ISSG.
    Spine (Phila Pa 1976); 2014 Feb 01; 39(3):233-42. PubMed ID: 24477081
    [Abstract] [Full Text] [Related]

  • 17. Posterior lumbar interbody fusion using recombinant human bone morphogenetic protein type 2 with cylindrical interbody cages.
    Haid RW, Branch CL, Alexander JT, Burkus JK.
    Spine J; 2004 Feb 01; 4(5):527-38; discussion 538-9. PubMed ID: 15363423
    [Abstract] [Full Text] [Related]

  • 18. Bone morphogenetic protein use in spine surgery in the United States: how have we responded to the warnings?
    Guzman JZ, Merrill RK, Kim JS, Overley SC, Dowdell JE, Somani S, Hecht AC, Cho SK, Qureshi SA.
    Spine J; 2017 Sep 01; 17(9):1247-1254. PubMed ID: 28456674
    [Abstract] [Full Text] [Related]

  • 19. Complications of rhBMP-2 utilization for posterolateral lumbar fusions requiring reoperation: a single practice, retrospective case series report.
    Hoffmann MF, Jones CB, Sietsema DL.
    Spine J; 2013 Oct 01; 13(10):1244-52. PubMed ID: 23973099
    [Abstract] [Full Text] [Related]

  • 20. Dose Adjustment Associated Complications of Bone Morphogenetic Protein: A Longitudinal Assessment.
    De Stefano FA, Elarjani T, Burks JD, Burks SS, Levi AD.
    World Neurosurg; 2021 Dec 01; 156():e64-e71. PubMed ID: 34530148
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.